Myriad RBM has manufactured and validated immunoassays based on Quanterix's single molecule array technology, Simoa.
The MRM-MS-based method combines use of conventional stable isotope-labeled peptide standards with a series of endogenous protein standards.
DSysMap combines mutation information with protein interaction data to provide a clearer picture of functional changes associated with the development of complex diseases.
The group's effort looked at the development steps required for successful implementation of MRM-MS assays as well as promising technical advances.
The firm is now clinically validating a mass spec-based test for quantifying native insulin and its therapeutic analogs and another test for type 2 diabetes.
In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.
Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.
Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.
Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.